2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
05/09/17Seattle Genetics to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--May 9, 2017-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16 at 9:20 a.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Sea... 
Printer Friendly Version
05/05/17Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132)
BOTHELL, Wash.--(BUSINESS WIRE)--May 5, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc. (Nasdaq: IMMU) for sacituzumab govitecan (IMMU-132) and settle the related litigation. The license agreement had not yet closed due to legal action brought by an Immunomedics stockholder challenging the transaction. The termination and set... 
Printer Friendly Version
04/27/17Seattle Genetics Reports First Quarter 2017 Financial Results
-First Quarter 2017 Revenues Were $109.1 Million, Including $70.3 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial Expected in 2017- -ADCETRIS Supplemental Biologics License Application for Cutaneous T-Cell Lymphoma Planned in Mid-2017- -Regulatory Discussions Support Planned Pivotal Trial of Enfortumab Vedotin (ASG-22ME) in Metastatic Urothelial Canc... 
Printer Friendly Version
04/06/17Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 27, 2017
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 6, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 27, 2017, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE acce... 
Printer Friendly Version
04/03/17Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 3, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted multiple data presentations that support the company’s advancing antibody-drug conjugate (ADC) and immuno-oncology programs at the upcoming 108th Annual Meeting of the American Association for Cancer Research (AACR) being held April 1-5, 2017, in Washington, D.C. The presentations describe the ability of ADCETRIS... 
Printer Friendly Version
03/30/17Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting
-14 presentations, including four orals, illustrate advances in ADC technology and multiple development programs- BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 30, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced its broad presence at the upcoming 108th Annual Meeting of the American Association for Cancer Research (AACR) being held April 1 to 5, 2017, in Washington, D.C., including 14 presentations ... 
Printer Friendly Version
03/06/17FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 6, 2017-- Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold announced on December 27, 2016 on phase 1 trials of vadastuximab talirine (SGN-CD33A; 33A) in acute myeloid leukemia (AML). “The clinical hold on our early-stage vadastuximab talirine clinical trials has been resolved through a com... 
Printer Friendly Version
03/01/17Seattle Genetics to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 1, 2017-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section. Cowen and Company 37th Annual Health Care Conference Wednesday, March 8, 10:40 a.m. Eastern Time,... 
Printer Friendly Version
02/13/17Seattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 13, 2017-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15 at 2:30pm Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics ... 
Printer Friendly Version
02/10/17Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors
-Seattle Genetics to Lead Development, Manufacturing and Commercialization of Sacituzumab Govitecan Globally- -Planned BLA for Triple Negative Breast Cancer Indication; Other Solid Tumors Being Explored in the Clinic- -Conference Call Today at 8:30 a.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agre... 
Printer Friendly Version
02/09/17Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results
-Fourth Quarter 2016 Revenues Were $105.3 Million, Including $70.8 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales- -ADCETRIS Supplemental Biologics License Application for Cutaneous T-Cell Lymphoma Planned in Mid-2017- -Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial Expected in 2017 and from Phase 3 ECHELON-2 Trial in 2018- -Regulatory Discussions Planned to Advance Enfortumab Vedotin (ASG-... 
Printer Friendly Version
01/19/17Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results on February 9, 2017
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 19, 2017-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2016 financial results on Thursday, February 9, after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/05/17Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
-SGN-CD352A, a Novel Antibody-Drug Conjugate (ADC), Represents Seattle Genetics’ 9th Clinical Stage Program in a Robust Pipeline of Empowered Antibody Therapies- -Preclinical Data Showing Potent Antitumor Activity of SGN-CD352A in B-cell Cancers Presented at the 2016 American Association of Cancer Research Annual Meeting- BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 5, 2017-- Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnolog... 
Printer Friendly Version